| 1 |
Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2019, 380(1)：45-56.
|
| 2 |
U．S. Food and Drug Administration. YESCARTA®(axicabtagene ciloleucel) suspension for intravenous infusion[EB/OL]. [2021-11-07].
URL
|
| 3 |
U．S. Food and Drug Administration. KYMRIAH®(tisagenlecleucel) suspension for intravenous infusion[EB/OL]. [2021-11-07].
URL
|
| 4 |
U．S. Food and Drug Administration. BREYANZI®(lisocabtagene maraleucel) suspension for intravenous infusion[EB/OL]. [2021-11-07].
URL
|
| 5 |
U．S. Food and Drug Administration. ABECMA®(idecabtagene vicleucel) suspension for intravenous infusion[EB/OL]. [2021-11-07].
URL
|
| 6 |
U．S. Food and Drug Administration. TECARTUS®(brexucabtagene autoleucel) suspension for intravenous infusion[EB/OL]. [2021-11-07].
URL
|
| 7 |
U．S. Food and Drug Administration. CARVYKTI™(ciltacabtagene autoleucel) suspension for intravenous infusion[EB/OL]. [2022-02-01].
URL
|
| 8 |
Wudhikarn K, Palomba ML, Pennisi M, et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma[J]. Blood Cancer J, 2020, 10(8)：79.
|
| 9 |
Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20(1)：31-42.
|
| 10 |
Park JH, Romero FA, Taur Y, et al. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells[J]. Clin Infect Dis, 2018, 67(4)：533-540.
|
| 11 |
Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy[J]. Blood, 2018, 131(1)：121-130.
|
| 12 |
Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells[J]. Biol Blood Marrow Transplant, 2020, 26(1)：26-33.
|
| 13 |
Haidar G, Dorritie K, Farah R, et al. Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis[J]. Clin Infect Dis, 2020, 71(3)：672-676.
|
| 14 |
Garner W, Samanta P, Dorritie K, et al. The burden of infections prior to chimeric antigen receptor (CAR) modified T-cell therapy predicts post-CAR T-cell infectious complications[J]. Open Forum Infect Dis, 2020, 7(Suppl 1): S583.
|
| 15 |
Vora SB, Waghmare A, Englund JA, et al. Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults[J]. Open Forum Infect Dis, 2020, 7(5)：ofaa121.
|
| 16 |
Los-Arcos I, Iacoboni G, Aguilar-Guisado M, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper[J]. Infection, 2021, 49(2)：215-231.
|
| 17 |
Wang Y, Liu Y, Tan X, et al. Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection[J]. Leukemia, 2020, 34(10)：2704-2707.
|
| 18 |
Lai P, Chen X, Qin L, et al. The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection[J]. Leukemia, 2020, 34(10)：2790-2793.
|
| 19 |
中国抗癌协会血液肿瘤专业委员会， 中华医学会血液学分会. 靶向B细胞和浆细胞的CAR-T细胞治疗中防治乙型肝炎病毒再激活的中国专家共识(2021年版)[J]. 中华血液学杂志， 2021, 6(42)：441-446.
|
| 20 |
Cao W, Wei J, Wang N, et al. Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy[J]. Blood, 2020, 136(4)：516-519.
|
| 21 |
Yang C, Xie M, Zhang K, et al. Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection[J]. Leukemia, 2020, 34(11)：3055-3059.
|
| 22 |
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med, 2014, 371(16)：1507-1517.
|
| 23 |
Doan A, Pulsipher MA. Hypogammaglobulinemia due to CAR T-cell therapy[J]. Pediatr Blood Cancer, 2018, 65(4)．
|
| 24 |
Wang Y, Li C, Xia J, et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma[J]. Blood Adv, 2021, 5(23)：5290-5299.
|
| 25 |
Kyriakidis I, Vasileiou E, Rossig C, et al. Invasive fungal diseases in children with hematological malignancies treated with therapies that target cell surface antigens: monoclonal antibodies, immune checkpoint inhibitors and CAR T-cell therapies[J]. J Fungi (Basel), 2021, 7(3)：186.
|
| 26 |
Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy[J]. Biomark Res, 2018, 6：4.
|
| 27 |
Trzeciak A, Pietropaoli AP, Kim M. Biomarkers and associated immune mechanisms for early detection and therapeutic management of sepsis[J]. Immune Netw, 2020, 20(3)：e23.
|
| 28 |
Luo H, Wang N, Huang L, et al. Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy[J]. J Immunother Cancer, 2019, 7(1)：271.
|
| 29 |
《中华传染病杂志》编辑委员会. 中国宏基因组学第二代测序技术检测感染病原体的临床应用专家共识[J]. 中华传染病杂志， 2020, 38(11)：681-689.
|
| 30 |
Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO Guideline[J]. J Clin Oncol, 2021, 39(35)：3978-3992.
|
| 31 |
Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)[J]. Ann Oncol, 2022, 33(3)：259-275.
|
| 32 |
中华医学会血液学分会， 中国医师协会血液科医师分会. 中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南(2020年版)[J]. 中华血液学杂志， 2020, 41(12): 969-978.
|
| 33 |
Jolles S, Michallet M, Agostini C, et al. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus[J]. Eur J Haematol, 2021, 106(4)：439-449.
|
| 34 |
中华医学会血液学分会感染学组， 中华医学会血液学分会淋巴细胞疾病学组， 中国临床肿瘤学会(CSCO)抗淋巴瘤联盟. 血液肿瘤免疫及靶向药物治疗相关性感染预防及诊治中国专家共识(2021年版)[J]. 中华血液学杂志， 2021，42(9)：717-727.
|
| 35 |
Ullmann AJ, Schmidt-Hieber M, Bertz H, et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016[J]. Ann Hematol, 2016, 95(9)：1435-1455.
|
| 36 |
Bernardes M, Hohl TM. Fungal infections associated with the use of novel immunotherapeutic agents[J]. Curr Clin Microbiol Rep, 2020, 7(4)：142-149.
|
| 37 |
Chinese XDR Consensus Working Group, Guan X, He L, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement[J]. Clin Microbiol Infect, 2016, 22(Suppl 1)：S15-S25.
|
| 38 |
王明贵 译. 广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制：中国专家共识[J]. 中国感染与化疗杂志， 2017, 17(1)：82-92.
|
| 39 |
中华医学会血液学分会， 中国医师协会血液科医师分会. 血液肿瘤患者碳青霉烯类耐药的肠杆菌科细菌(CRE)感染的诊治与防控中国专家共识(2020年版)[J]. 中华血液学杂志， 2020, 41 (11)：881-889.
|
| 40 |
中国医师协会血液科医师分会， 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第六次修订版)[J]. 中华内科杂志， 2020, 59 (10)：754-763.
|
| 41 |
Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5)：439-448.
|